-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Nurix Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q1 2025.
- Nurix Therapeutics, Inc. Operating Income (Loss) for the quarter ending February 28, 2025 was -$62.9M, a 39% decline year-over-year.
- Nurix Therapeutics, Inc. Operating Income (Loss) for the twelve months ending February 28, 2025 was -$231M, a 46.6% decline year-over-year.
- Nurix Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$213M, a 37.4% decline from 2023.
- Nurix Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$155M, a 15.7% increase from 2022.
- Nurix Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$184M, a 56% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)